Catalyst Wire Dossier Catalyst Wire Dossier
EMA approval · 2023-04-25

EMA Authorised: Stocrin (efavirenz) — Merck Sharp & Dohme B.V.

View source ↗

Summary

EFAVIRENZ (Stocrin) has been authorised by the EMA for HIV infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Stocrin (efavirenz)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: Merck Sharp & Dohme B.V.. Decision date: 14/04/2023